Clinical Trial Update: Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for afatinib plus prednisone in advanced squamous cell carcinoma of the lung. The study status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Afatinib (afatinib)
• PREDNISONE (Prednisone)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Advanced Squamous Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING